TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective study

Cancer Research

Volumn 66, Issue 13, 2006, Pages 6871-6876

  Gormally, Emmanuelle ^a,b   Vineis, Paolo ^c,d   Matullo, Giuseppe ^c,d   Veglia, Fabrizio ^d   Caboux, Elodie ^a   Le Roux, Emilie ^a   Peluso, Marco ^e   Garte, Seymour ^f   Guarrera, Simonetta ^d   Munnia, Armelle ^e   Airoldi, Luisa ^g   Autrup, Herman ⁱ   Malaveille, Christian ^a   Dunning, Alison ^l   Overvad, Kim ^j,k   Tjønneland, Anne ⁿ   Lund, Eiliv ^o   Clavel Chapelon, Françoise ^p   Boeing, Heiner ^q   Trichopoulou, Antonia ^r   Palli, Domenico ^e   Krogh, Vittorio ^h   Tumino, Rosario ^s   Panico, Salvatore ^t   Bueno De Mesquita, H Bas ^u   Peeters, Petra H ^v   Pera, Guillem ^w   Martinez, Carmen ^x   Dorronsoro, Miren ⁱ   Barricarte, Aurelio ^y   Navarro, Carmen ^z   Quirós, José Ramón ^aa   Hallmans, Göran ^ab   Day, Nicholas E ^m   Key, Timothy J ^ac   Saracci, Rodolfo ^a   Kaaks, Rudolf ^a   Riboli, Elio ^a   Hainaut, Pierre ^a   more..

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITÉ CATHOLIQUE DE LYON   (France)

^c UNIVERSITY OF TURIN   (Italy)

^d ISI Foundation   (Italy)

^e CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^f Genetics Research Institute   (Italy)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ National Cancer Istitute ^*  (Spain)

^j AALBORG UNIVERSITY HOSPITAL   (Denmark)

^k AARHUS UNIVERSITY   (Denmark)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^o UNIVERSITY OF TROMSØ   (Norway)

^p INSERM   (France)

^q GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^r UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^s CIVILE M P AREZZO HOSPITAL   (Italy)

^t UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^u NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^v UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^w CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^x ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^y INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^z DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^aa Direccion General de Salud Publica   (Spain)

^ab UMEÅ UNIVERSITY   (Sweden)

^ac UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ONCOPROTEIN; PROTEIN KRAS2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; BLOOD ANALYSIS; CANCER CELL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CARCINOGENESIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW UP; GEL ELECTROPHORESIS; GENDER; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKEMIA; LUNG CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING;

ADULT; AGED; CASE-CONTROL STUDIES; DNA; FEMALE; GENES, P53; HUMANS; LEUKEMIA; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 33746155812     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4556     Document Type: Article

References (29)

1. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 2002;28:255-71.
2. Kirk GD, Lesi OA, Mendy M, et al. 249(Ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 2005;24:5858-67.
3. Szymanska K, Lesi OA, Kirk GD, et al. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in The Gambia, West Africa Int J Cancer 2004;110:374-9.
4. Jackson PE, Kuang SY, Wang JB, et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis 2003;24:1657-63.
5. Kopreski MS, Benko FA, Borys DJ, et al. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 2000;92:918-23.
6. Allan JM, Hardie LJ, Briggs JA, et al. Genetic alterations in bronchial mucosa and plasma DNA from individuals at high risk of lung cancer. Int J Cancer 2001;91:359-65.
7. Gormally E, Hainaut P, Caboux E, et al. Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer 2004;111:746-9.
8. Peluso M, Hainaut P, Airoldi L, et al. Methodology of laboratory measurements in prospective studies on gene-environment interactions: the experience of Gen-Air. Mutat Res 2005;574:92-104.
9. Bingham S, Riboli E. Diet and cancer - the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer 2004;4:206-15.
10. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755-65.
11. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
12. Peluso M, Munnia A, Hoek G, et al. DNA adducts and lung cancer risk: a prospective study. Cancer Res 2005;65:8042-8.
13. le Calvez F, Ahman A, Tonisson N, et al. Arrayed primer extension resequencing of mutations in the TP53 tumor suppressor gene: comparison with denaturing HPLC and direct sequencing. Clin Chem 2005;51:1284-7.
14. Taniere P, Martel-Planche G, Puttawibul P, et al. TP53 mutations and MDM2 gene amplification in squamous-cell carcinomas of the esophagus in south Thailand. Int J Cancer 2000;88:223-7.
15. Mulcahy HE, Lyautey J, Lederrey C, et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998;4:271-5.
16. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.
17. Matullo G, Dunning AM, Guarrera S, et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 2006. Epub.
18. Jacobs G, Tscholl E, Sek A, et al. Enrichment polymerase chain reaction for the detection of Ki-ras mutations: relevance of Taq polymerase error rate, initial DNA copy number, and reaction conditions on the emergence of false-positive mutant bands. J Cancer Res Clin Oncol 1999;125:395-401.
19. Al Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 2003;97:2064-75.
20. Olderoy G, Daehlin L, Ogreid D. Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder. Anticancer Res 1998;18:2675-8.
21. Uchida T, Wada C, Ishida H, et al. Infrequent involvement of mutations on neurofibromatosis type 1, H-ras, K-ras and N-ras in urothelial tumors. Urol Int 1995;55:63-7.
22. Jebar AH, Hurst CD, Tomlinson DC, et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24:5218-25.
23. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001;20:1973-80.
24. Trombino S, Neri M, Puntoni R, et al. Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer. Clin Chem 2005;51:1313-4.
25. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108-12.
26. Hoque MO, Lee CC, Cairns P, Schoenberg M, Sidransky D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 2003;63:2216-22.
27. van Rhijn BW, Lurkin I, Radvanyi F, et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate 8. Cancer Res 2001;61:1265-8.
28. Wang Y, Spitz MR, Zhu Y, et al. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst) 2003;2:901-8.
29. Green J, Banks E, Berrington A, et al. N-acetyl-transferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. Br J Cancer 2000;83:412-7.